Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy

Dr. Armand Balboni appointed as Chair of the Board and moves to the U.S. Air Force Academy to take over as Principal Investigator for the ATI-1701 program; and Dr. Don Cilla promoted to President and... | November 14, 2022

Related Keywords

United States ,Ian Mortimer ,Don Cilla ,Theresa Matkovits ,Armand Balboni ,Us Department Of Defense ,Department Of Defense ,Us National Institutes Of Health ,Drug Administration ,Company Or Appili ,Us Air Force Academy ,Appili Therapeutics Inc ,Life Sciences Research Center ,Appili Therapeutics ,Joint Science ,Technology Office ,Defense Threat Reduction Agency ,Force Academy ,Investigational New Drug ,United States Food ,Priority Review ,Chief Development Officer ,Chief Executive Officer ,Additional Board ,Lead Independent ,Board Chair ,Appili Therapeutics Inc Stock Exchange ,News ,Information ,Press Release ,Farmand ,Balboni ,Appointed ,Us ,Hair ,F ,The ,Board ,End ,Moves ,O ,Fir ,Force ,Academy ,Lake ,Dover ,Principal ,Investigator ,Or ,Son ,Villa ,Romoted ,Resident Apli Ca03783r1073 ,